Cardiology

Study compares anticoagulants for antiphospholipid syndrome

(HealthDay)—In thrombotic antiphospholipid antibody syndrome (APS), rivaroxaban is not noninferior to dose-adjusted vitamin K antagonists (VKAs), according to a study published online Oct. 15 in the Annals of Internal Medicine.

Cardiology

Rivaroxaban cuts recurrent blood clots in obese patients

(HealthDay)—Real-world evidence shows that rivaroxaban reduces the risk for recurrent venous thromboembolism (VTE) in morbidly obese patients, with similar safety and efficacy as warfarin, according to a study published ...

Cardiology

No clear benefit for rivaroxaban after hospital discharge

(HealthDay)—Rivaroxaban does not lower risk of symptomatic venous thromboembolism and related death in medical patients after hospital discharge, compared to placebo, according to a study published in the Sept. 20 issue ...

Cardiology

Drug dosage recommendation model

NUS pharmaceutical scientists have developed a prediction model to guide dosage adjustments of rivaroxaban, an oral anticoagulant (blood thinner), in renal-impaired patients taking amiodarone. This is to reduce the risk of ...

Neuroscience

Warfarin, rivaroxaban similarly safe, effective

(HealthDay)—For cases of mild atrial fibrillation (AF)-related acute ischemic stroke, rivaroxaban and warfarin are similarly safe and effective at preventing recurrent stroke, according to a study published online Sept. ...

page 1 from 3